BridgeBio Oncology Therapeutics, Inc.(BBOT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
BBOT Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for BridgeBio Oncology Therapeutics, Inc. (BBOT), a Healthcare sector company. BBOT is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), BridgeBio Oncology Therapeutics, Inc. reports net income of $-56.5M, free cash flow of $-44.4M. Top institutional holders of BBOT by reported 13-F value include Cormorant Asset Management, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Omega Fund Management, based on the most recent SEC filings. BBOT trades on the Nasdaq exchange and files with the SEC under CIK 1869105. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BBOT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BridgeBio Oncology Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-56.5M
Free Cash Flow
Q2 2026
$-44.4M
ROIC
Q2 2026
-74.5%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-80.5% YoYOperating Income
-80.3% YoYEPS (Diluted)
+99.9% YoYTotal Assets
+172.9% YoYOp. Cash Flow
-107.0% YoYFree Cash Flow
-107.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Net Income | $-134.0M -80.5% | $-74.3M -178051.7% | $-41.7K | — |
| Operating Income | $-145.8M -80.3% | $-80.9M -193853.3% | $-41.7K | — |
| EPS (Diluted) | $-4.30 +99.9% | $-5756.41 | — | — |
| Total Assets | $448.4M +172.9% | $164.3M +49255.4% | $332.9K | — |
| Operating Cash Flow | $-113.9M -107.0% | $-55.0M | — | — |
| Free Cash Flow | $-114.5M -107.9% | $-55.1M | — | — |
Get alerted when BBOT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for BridgeBio Oncology Therapeutics, Inc. including:
Top Institutional Holders of BBOT
Cormorant Asset Management, LP
$136.2M17,878,594 shDEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$37.2M4,885,446 shOmega Fund Management, LLC
$25.1M3,289,661 shEcoR1 Capital, LLC
$21.5M2,823,126 shAlphabet Inc.
$21.5M2,823,126 shWELLINGTON MANAGEMENT GROUP LLP
$21.3M2,789,302 shEnavate Sciences GP, LLC
$20.0M2,626,946 shCITADEL ADVISORS LLC
$19.9M2,617,827 shNovo Holdings A/S
$17.1M2,250,000 shBlackRock, Inc.
$16.4M2,154,040 sh
| Fund | Value | Shares |
|---|---|---|
| Cormorant Asset Management, LP | $136.2M | 17,878,594 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | $37.2M | 4,885,446 |
| Omega Fund Management, LLC | $25.1M | 3,289,661 |
| EcoR1 Capital, LLC | $21.5M | 2,823,126 |
| Alphabet Inc. | $21.5M | 2,823,126 |
| WELLINGTON MANAGEMENT GROUP LLP | $21.3M | 2,789,302 |
| Enavate Sciences GP, LLC | $20.0M | 2,626,946 |
| CITADEL ADVISORS LLC | $19.9M | 2,617,827 |
| Novo Holdings A/S | $17.1M | 2,250,000 |
| BlackRock, Inc. | $16.4M | 2,154,040 |
More Healthcare Companies
View all Healthcare →Put BBOT on your watchlist
Track score changes the day BridgeBio Oncology Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is BBOT a good stock to buy?
13F Pro's AI-powered analysis of BridgeBio Oncology Therapeutics, Inc. (BBOT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BBOT are available on the BBOT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. BBOT is classified as a small company.
Which hedge funds own BBOT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BBOT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BridgeBio Oncology Therapeutics, Inc.'s investment landscape.